June 12, 2017
2 min read
Save

FDA warning, alopecia study top dermatology reads for week

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Study findings that platelet-rich plasma showed efficacy in combination treatment for androgenetic alopecia was among the top read articles of the past week on Healio.com/Dermatology.

Other widely-read articles included study findings that there was a marked variation in the number of stages per case of Mohs micrographic surgery, and the FDA’s public warning of unapproved versions of Juvéderm:

Variation seen in number of stages per case of Mohs micrographic surgery

There was a marked variation in the number of stages per case of Mohs micrographic surgery of head and neck, genitalia, hands and feet skin cancers, according to study results published in JAMA Dermatology.

Researchers used Medicare Part B claims data to conduct a retrospective analysis between 2012 and 2014 of 2,305 individual billing physicians (66.8% male) who received Medicare payments for performing Mohs micrographic surgery (MMS). Read more

Platelet-rich plasma shows efficacy in combination treatment for androgenetic alopecia

Platelet-rich plasma in combination with 5% minoxidil solution showed efficacy in hair regrowth for patients with androgenetic alopecia compared with the combination with oral finasteride, according to study results recently published in Dermatologic Surgery.

Researchers studied 25 patients with androgenetic alopecia (13 females; mean age, 39.9 years). Read more

FDA warns of unapproved versions of Juvéderm

The FDA announced it has updated its dermal fillers website to include a public warning about unapproved versions of Juvéderm, including Juvéderm Ultra 2, 3, or 4, which are being sold and distributed illegally in the United States.

Juvéderm (hyaluronic acid, Allergan) should only be injected and sold by or on the prescription of a licensed health care provider, the FDA reported in a press release. Read more

Allergan to acquire breast implant insertion device

Allergan announced that its subsidiary, Allergan Sales LLC, has agreed to acquire Keller Medical, the developer of the Keller Funnel used in breast augmentation and reconstruction procedures.

The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during the procedures. Read more

Lower concentrations of hyaluronidase effective at degrading hyaluronic acid

Lower concentrations of hyaluronidase were as effective as higher concentrations at degrading hyaluronic acid fillers, according to study results published in Dermatologic Surgery.

Margit L. W. Juhász, MD, of the dermatology department, Icahn School of Medicine at Mount Sinai, New York, and colleagues conducted a blinded randomized study of 15 volunteers (mean age, 27.2 years; 53.3% women). Read more